Endoscopy Procedures — Cost, Top Hospitals & Success Rates | MyMedicPlus

Endoscopy is a broad category of minimally invasive medical procedures that use a flexible or rigid fibre-optic instrument called an endoscope to visualise, diagnose, and treat disorders of internal body structures — most commonly the gastrointestinal (GI) tract. A modern flexible endoscope consists of a long, thin tube housing a high-definition camera, light source, suction-irrigation channels, and a working channel through which diagnostic and therapeutic instruments can be passed — including biopsy forceps, snares, haemostasis clips, injection needles, and ablation probes.

Upper gastrointestinal endoscopy (oesophago-gastro-duodenoscopy, or OGD/EGD) and lower GI endoscopy (colonoscopy, sigmoidoscopy) are among the most frequently performed procedures in modern medicine. Globally, hundreds of millions of endoscopic procedures are performed annually. Advances in endoscope technology — including high-definition white light, narrow band imaging (NBI), chromoendoscopy, confocal laser endomicroscopy, and artificial intelligence-assisted polyp detection — have transformed endoscopy from a purely diagnostic modality into a powerful therapeutic platform capable of treating a wide spectrum of pathology without the need for open surgery.

Most upper GI endoscopies are performed under intravenous conscious sedation (typically midazolam with or without an opioid such as fentanyl) or propofol deep sedation administered by an anaesthesiologist or nurse anaesthetist. Colonoscopy is almost universally performed under sedation. Some upper endoscopies are performed with pharyngeal local anaesthetic spray alone (unsedated), particularly in high-volume screening programmes. The procedure is performed by a gastroenterologist, surgical endoscopist, or trained specialist in a purpose-equipped endoscopy unit with continuous vital-sign monitoring.

Endoscopy is used to diagnose and treat a wide range of conditions affecting the digestive system and beyond:

• Gastro-oesophageal reflux disease (GORD/GERD): Barrett's oesophagus surveillance; ablation of dysplastic Barrett's epithelium with radiofrequency ablation (RFA).
• Peptic ulcer disease: Diagnosis of gastric and duodenal ulcers; haemostasis of actively bleeding ulcers using injection therapy, thermal coagulation, or haemostatic clips; biopsy for Helicobacter pylori testing.
• Colorectal polyp detection and removal (polypectomy): The cornerstone of colorectal cancer prevention. Adenomatous polyps are identified and removed via hot or cold snare, endoscopic mucosal resection (EMR), or endoscopic submucosal dissection (ESD).
• Colorectal cancer screening: Colonoscopy is the gold-standard screening test for colorectal cancer in average-risk adults from age 45–50.
• Upper GI bleeding: Haemostasis of bleeding from oesophageal varices (variceal band ligation, sclerotherapy), Mallory-Weiss tears, Dieulafoy lesions, and ulcers.
• Coeliac disease: Duodenal biopsy to confirm villous atrophy.
• Inflammatory bowel disease (IBD): Ileocolonoscopy with biopsies for diagnosis, surveillance, and disease activity assessment in Crohn's disease and ulcerative colitis.
• Dysphagia: Diagnosis of oesophageal strictures, rings (Schatzki), achalasia, and eosinophilic oesophagitis; balloon dilation of strictures.
• Foreign body removal: Retrieval of swallowed objects from the oesophagus or stomach.
• ERCP (Endoscopic Retrograde Cholangiopancreatography): Combined endoscopic-fluoroscopic procedure for diagnosis and treatment of bile duct stones, biliary strictures, and pancreatic duct disorders.
• Endoscopic ultrasound (EUS): High-resolution ultrasound-guided evaluation of pancreatic masses, submucosal lesions, and staging of upper GI cancers; FNA biopsy under direct ultrasound guidance.

Endoscopy is a widely applicable procedure with few absolute contraindications. Appropriate candidates include:

• Patients with unexplained upper abdominal symptoms (dyspepsia, heartburn, regurgitation, dysphagia, early satiety) persisting despite 4–8 weeks of empirical therapy, or with alarm features (weight loss, anaemia, dysphagia, haematemesis, family history of upper GI malignancy).
• Adults aged 45–50 and above with average risk for colorectal cancer who are due for screening colonoscopy, or those with a family history of colorectal cancer or polyps (earlier screening recommended).
• Patients with known IBD requiring disease surveillance or therapy.
• Patients with gastrointestinal bleeding (haematemesis, melaena, rectal bleeding, iron deficiency anaemia of obscure origin).
• Those who are adequately anticoagulated or can safely bridge anticoagulation per current guidelines (most diagnostic endoscopies can proceed on antiplatelet agents; therapeutic procedures require temporary cessation of anticoagulants).

Absolute contraindications are rare and include perforation or suspected perforation of a viscus, haemodynamic instability precluding safe sedation, and lack of a safe airway. Patients with significant cardiorespiratory co-morbidities require an anaesthetic assessment before sedated endoscopy. Pregnancy is not a contraindication to urgent diagnostic endoscopy, though elective procedures are deferred to the second trimester when possible.

Endoscopic procedures span a wide clinical spectrum. The major categories are:

• Upper GI endoscopy (OGD/EGD/Gastroscopy): A 10–12 mm flexible endoscope is introduced through the mouth to examine the oesophagus, stomach, and duodenum. Diagnostic (biopsy, photodocumentation) and therapeutic (polypectomy, haemostasis, dilation, ablation) functions are combined. Duration: 15–30 minutes.
• Colonoscopy: A 10–13 mm flexible colonoscope is introduced per rectum after bowel preparation to examine the entire colon and terminal ileum. Gold-standard for CRC screening and polypectomy. Duration: 20–45 minutes.
• Flexible sigmoidoscopy: Examination of the rectum and left colon only; shorter preparation and procedure, but lower diagnostic yield than full colonoscopy. Duration: 10–20 minutes.
• Endoscopic mucosal resection (EMR): Injection of fluid into the submucosal layer lifts a flat or sessile polyp/early cancer, which is then removed en-bloc with a snare. Used for lesions up to 20–25 mm.
• Endoscopic submucosal dissection (ESD): Precise dissection of the submucosal layer using a specialised knife electrode, enabling en-bloc removal of large (>20 mm) or complex mucosal neoplasms — the preferred technique in East Asian centres for early gastric and colorectal cancer.
• ERCP (Endoscopic Retrograde Cholangiopancreatography): A side-viewing duodenoscope cannulates the biliary and pancreatic ducts. Therapeutic manoeuvres include sphincterotomy, stone extraction, stent placement, and biliary dilation.
• Endoscopic ultrasound (EUS): An ultrasound transducer at the tip of the endoscope provides high-resolution images of structures beyond the gut wall; used for tumour staging, cyst evaluation, and FNA biopsy.
• Capsule endoscopy: A swallowable wireless camera capsule captures images of the small bowel (not accessible by standard endoscopes) over 8–12 hours. Used for obscure GI bleeding, suspected Crohn's disease, and small bowel tumours.
• Bronchoscopy: A flexible bronchoscope examines the airways (trachea, bronchi) for lung cancer staging, foreign body removal, and bronchoalveolar lavage. Technologically related but respiratory (not GI) in application.

Endoscopy provides diagnostic and therapeutic benefits that have transformed the management of GI diseases:

• Definitive diagnosis without surgery: Direct visualisation and biopsy from any GI segment yields histological diagnosis with sensitivity and specificity far exceeding non-invasive modalities for most conditions.
• Cancer prevention: Colonoscopy with polypectomy reduces colorectal cancer incidence by up to 76–90% by removing pre-cancerous polyps before malignant transformation. This is one of the most impactful cancer prevention interventions in modern medicine.
• Immediate treatment at time of diagnosis: Bleeding ulcers can be treated, polyps removed, strictures dilated, and bile duct stones extracted — all in the same session as diagnosis.
• Avoidance of major surgery: Conditions previously requiring laparotomy — such as early gastric cancer, large colonic polyps, and bile duct stones — can now be treated endoscopically as day procedures.
• Safety and repeatability: Endoscopy is well tolerated with a very low complication rate. Surveillance endoscopy can be repeated at regular intervals for high-risk patients.
• Short procedure and recovery: Most endoscopies are completed within 15–60 minutes; patients recover within 1–4 hours and return home the same day.
• Advanced imaging: NBI, chromoendoscopy, and AI-assisted detection improve adenoma detection rates (ADR) by 20–30% compared to standard white-light colonoscopy, further enhancing cancer prevention outcomes.

Endoscopy is among the safest medical procedures but complications, though rare, can occur:

• Perforation: The most serious complication. Diagnostic upper endoscopy: 1 in 2,500–10,000. Diagnostic colonoscopy: 1 in 1,000–2,000. Therapeutic procedures (ESD, ERCP, dilation) carry higher perforation rates (1–5%). Most perforations are manageable endoscopically (clips) or surgically.
• Bleeding: Post-polypectomy bleeding occurs in 1–6 per 1,000 colonoscopies. Usually self-limiting or treatable endoscopically. Delayed bleeding (up to 2 weeks post-procedure) can occur after polypectomy or ESD.
• Sedation-related adverse events: Cardiorespiratory depression, oxygen desaturation, and aspiration are uncommon with appropriate monitoring but increase in patients with obesity, obstructive sleep apnoea, or significant cardiac disease.
• ERCP-specific: Post-ERCP pancreatitis: The most common serious complication of ERCP, occurring in 3–5% of cases. Severe pancreatitis is rare (<0.5%). Risk is reduced by prophylactic rectal indomethacin and pancreatic stenting in high-risk cases.
• Infection: Endoscopy-related infections are rare with properly disinfected equipment. Bacteraemia is transient and clinically relevant only in patients with cardiac valvular lesions or prosthetic valves (antibiotic prophylaxis is no longer routinely recommended).
• Aspiration pneumonia: A risk during upper endoscopy, particularly in patients with gastroparesis or active upper GI bleeding. Endotracheal intubation may be required in high-risk situations.
• Missed lesions: Adenoma miss rates for colonoscopy are approximately 6–12% for polyps <10 mm. High-definition colonoscopy, adequate bowel preparation, and slow withdrawal time (minimum 6 minutes) minimise this risk.

Immediately after procedure: Patients recover in a monitored unit for 30–90 minutes until sedation effects resolve. Vital signs are monitored. Light bloating and mild cramping are common after colonoscopy from insufflation gas. A responsible adult must accompany the patient home; driving is not permitted on the day of a sedated procedure.

Diet and activity: After upper endoscopy: normal diet can be resumed when the throat numbness (if local spray was used) has resolved, typically within 1 hour. After colonoscopy: light diet is recommended for the remainder of the day; normal diet resumes the following day. Most patients resume normal activities the following day. Those who had therapeutic procedures (EMR, ESD, variceal banding) receive additional specific instructions including a period of soft diet or proton pump inhibitor therapy.

Result communication: Biopsy results are usually available within 3–7 business days and are communicated by the referring physician or endoscopist. Immediate findings (polyp removal, haemostasis achieved, stricture dilated) are documented in the endoscopy report provided to the patient at discharge.

Surveillance intervals: Post-colonoscopy surveillance intervals depend on findings. No polyps: 10-year interval. 1–2 tubular adenomas <10 mm: 7–10 years. 3–4 adenomas or high-risk features: 3 years. Advanced serrated lesions: 3 years. Patients with Barrett's oesophagus undergo upper endoscopy surveillance at 3–5 yearly intervals, with shorter intervals if dysplasia is detected.

Endoscopy costs vary widely depending on the type of procedure, country, and facility:

• Procedure type: Diagnostic upper endoscopy is the least expensive; ERCP, EUS, and ESD are significantly more complex and costly. Colonoscopy with polypectomy falls in the mid-range.
• Country: In the United States, an OGD costs USD 1,500–3,500; colonoscopy USD 2,500–5,000; ERCP USD 5,000–10,000. In India: OGD USD 150–400; colonoscopy USD 300–700; ERCP USD 600–2,000. In Thailand: OGD USD 300–700; colonoscopy USD 500–1,500. In Turkey: OGD USD 250–600.
• Sedation type: Propofol sedation administered by an anaesthesiologist adds USD 500–1,500 in the US; this cost is minimal in most Asian countries.
• Biopsy and pathology: Multiple biopsies increase the laboratory processing cost. Histopathological analysis of polypectomy specimens adds to the total.
• Therapeutic vs. diagnostic: Therapeutic procedures (EMR, ESD, variceal banding, stent placement) involve additional equipment and skill, increasing cost.
• Insurance: In the US, colonoscopy for CRC screening is covered with no co-pay under the Affordable Care Act. Diagnostic colonoscopy may incur a co-pay. Coverage for OGD varies.

Medical tourism for endoscopy is well-established. Patients from the US, UK, and Australia frequently seek procedures in India, Thailand, or Malaysia, where costs are 70–85% lower and wait times are negligible at accredited facilities.

Alternatives to endoscopy depend on the clinical indication:

• Faecal immunochemical testing (FIT): Non-invasive stool test for occult blood — a validated alternative to colonoscopy for CRC screening in average-risk individuals. A positive FIT mandates colonoscopy. Annual testing required; sensitivity for advanced adenomas (~40%) is lower than colonoscopy.
• CT colonography (virtual colonoscopy): CT-based 3D reconstruction of the colon — no sedation required. Comparable sensitivity to optical colonoscopy for polyps ≥6 mm. Disadvantage: cannot perform biopsy or polypectomy; detected polyps require follow-up colonoscopy.
• CT/MRI enterography: Cross-sectional imaging of the small bowel — an alternative to capsule endoscopy for suspected Crohn's disease, with good sensitivity for transmural disease and complications (strictures, fistulae).
• Barium swallow / upper GI series: Fluoroscopic study with oral contrast — largely superseded by upper endoscopy for most upper GI diagnoses but retained for dysphagia evaluation (especially motility disorders) and post-operative anatomy assessment.
• H. pylori non-invasive testing: Urea breath test and stool antigen test are validated alternatives to endoscopic biopsy for diagnosing H. pylori infection in patients without alarm features.
• Surgery: For conditions where endoscopic treatment has failed (large lesions not amenable to EMR/ESD, refractory bleeding, perforation) or for cancer beyond endoscopic cure, surgical resection is the definitive treatment.